Variant Bio Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 46

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $105M

  • Investors
  • 9

Variant Bio General Information

Description

Developer of medical therapies intended to improve global health by studying genes and health-related traits. The company uses sequencing technology, statistical genetics, and machine learning to get insights from human genetics, which allows it to identify the basis and resistance of disease, making it an ideal match for drug discovery, enabling patients to have access to genomic drugs for unmet needs, including neurodegenerative, autoimmune, and cardiometabolic diseases.

Contact Information

Formerly Known As
Syngular
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1150 Eastlake Avenue East
  • Suite 1000
  • Seattle, WA 98109
  • United States
+1 (206)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 1150 Eastlake Avenue East
  • Suite 1000
  • Seattle, WA 98109
  • United States
+1 (206)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Variant Bio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 04-Nov-2021 $105M Completed Pre-Clinical Trials
2. Early Stage VC (Series A) 05-Aug-2020 Completed Pre-Clinical Trials
1. Seed Round 01-Jan-2018 $1.54M $1.54M Completed Startup
To view Variant Bio’s complete valuation and funding history, request access »

Variant Bio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Seed 513,027 $0.001000 8% $3 $3 1x $3 3.53%
To view Variant Bio’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Variant Bio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of medical therapies intended to improve global health by studying genes and health-related traits. The compan
Drug Discovery
Seattle, WA
46 As of 2026

Reykjavik, Iceland
 

Cambridge, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Variant Bio Competitors (3)

One of Variant Bio’s 3 competitors is Decode Genetics, a Formerly VC-backed company based in Reykjavik, Iceland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Decode Genetics Formerly VC-backed Reykjavik, Iceland
HiFiBiO Therapeutics Venture Capital-Backed Cambridge, MA
Genetix Biotherapeutics Private Equity-Backed Somerville, MA
You’re viewing 3 of 3 competitors. Get the full list »

Variant Bio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Variant Bio Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Cercano Management PE/Buyout Minority
General Catalyst Venture Capital Minority
SoftBank Investment Advisers Growth/Expansion Minority
Alexandria Venture Investments Venture Capital Minority
Alta Partners Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Variant Bio FAQs

  • When was Variant Bio founded?

    Variant Bio was founded in 2018.

  • Where is Variant Bio headquartered?

    Variant Bio is headquartered in Seattle, WA.

  • What is the size of Variant Bio?

    Variant Bio has 46 total employees.

  • What industry is Variant Bio in?

    Variant Bio’s primary industry is Drug Discovery.

  • Is Variant Bio a private or public company?

    Variant Bio is a Private company.

  • What is the current valuation of Variant Bio?

    The current valuation of Variant Bio is .

  • What is Variant Bio’s current revenue?

    The current revenue for Variant Bio is .

  • How much funding has Variant Bio raised over time?

    Variant Bio has raised $131M.

  • Who are Variant Bio’s investors?

    Cercano Management, General Catalyst, SoftBank Investment Advisers, Alexandria Venture Investments, and Alta Partners are 5 of 9 investors who have invested in Variant Bio.

  • Who are Variant Bio’s competitors?

    Decode Genetics, HiFiBiO Therapeutics, and Genetix Biotherapeutics are competitors of Variant Bio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process